Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Vacca

Showing results (321-330 of 347) with videos related to

Pageof 35
Sort By:
European Journal of Clinical Investigation|November 16, 2022
Early administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trialAlessia Ferrarini, Angelo Vacca, Antonio Giovanni Solimando, et al.
Journal of Clinical Medicine|July 21, 2019
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentAntonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, et al.
Journal of Clinical Medicine|September 13, 2025
The LUNET Project: Developing the Italian Systemic Erythematous Lupus NetworkIlaria Mormile, Luisa Brussino, Giorgio Walter Canonica, et al.
European Journal of Medicinal Chemistry|December 28, 2018
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viabilityMaria Laura Pati, Paola Vitale, Savina Ferorelli, et al.
The Journal of Pathology|October 26, 2018
Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomesMaria Antonia Frassanito, Vanessa Desantis, Lucia Di Marzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myelomaAnnunziata De Luisi, Arianna Ferrucci, Addolorata M L Coluccia, et al.
International Journal of Immunopathology and Pharmacology|December 9, 2016
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficienciesClementina Canessa, Jessica Iacopelli, Antonio Pecoraro, et al.
Frontiers in Immunology|March 29, 2021
Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral CentersFrancesco Cinetto, Riccardo Scarpa, Maria Carrabba, et al.
Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Journal of Clinical Immunology|April 21, 2022
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)Giuliana Giardino, Cinzia Milito, Vassilios Lougaris, et al.
Pageof 35

Showing results (321-330 of 347) with videos related to

Sort By:
Pageof 35
European Journal of Clinical Investigation|November 16, 2022
Early administration of tofacitinib in COVID-19 pneumonitis: An open randomised controlled trialAlessia Ferrarini, Angelo Vacca, Antonio Giovanni Solimando, et al.
Journal of Clinical Medicine|July 21, 2019
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor MicroenvironmentAntonio Giovanni Solimando, Matteo Claudio Da Vià, Sebastiano Cicco, et al.
Journal of Clinical Medicine|September 13, 2025
The LUNET Project: Developing the Italian Systemic Erythematous Lupus NetworkIlaria Mormile, Luisa Brussino, Giorgio Walter Canonica, et al.
European Journal of Medicinal Chemistry|December 28, 2018
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viabilityMaria Laura Pati, Paola Vitale, Savina Ferorelli, et al.
The Journal of Pathology|October 26, 2018
Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomesMaria Antonia Frassanito, Vanessa Desantis, Lucia Di Marzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2011
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myelomaAnnunziata De Luisi, Arianna Ferrucci, Addolorata M L Coluccia, et al.
International Journal of Immunopathology and Pharmacology|December 9, 2016
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficienciesClementina Canessa, Jessica Iacopelli, Antonio Pecoraro, et al.
Frontiers in Immunology|March 29, 2021
Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID): A Multicenter Retrospective Study of Patients From Italian PID Referral CentersFrancesco Cinetto, Riccardo Scarpa, Maria Carrabba, et al.
Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Journal of Clinical Immunology|April 21, 2022
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)Giuliana Giardino, Cinzia Milito, Vassilios Lougaris, et al.
Pageof 35